[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200601167A1 - Химически модифицированные малые молекулы - Google Patents

Химически модифицированные малые молекулы

Info

Publication number
EA200601167A1
EA200601167A1 EA200601167A EA200601167A EA200601167A1 EA 200601167 A1 EA200601167 A1 EA 200601167A1 EA 200601167 A EA200601167 A EA 200601167A EA 200601167 A EA200601167 A EA 200601167A EA 200601167 A1 EA200601167 A1 EA 200601167A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chemically modified
water
small molecules
modified small
penetration
Prior art date
Application number
EA200601167A
Other languages
English (en)
Other versions
EA015333B1 (ru
Inventor
Майкл Д. Бентли
Тэси Кс. Виегас
Ричард Р. Гудин
Лин Ченг
Ксуан Жао
Original Assignee
Нектар Терапьютикс Ал, Корпорейшен
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34700098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200601167(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Нектар Терапьютикс Ал, Корпорейшен filed Critical Нектар Терапьютикс Ал, Корпорейшен
Publication of EA200601167A1 publication Critical patent/EA200601167A1/ru
Publication of EA015333B1 publication Critical patent/EA015333B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/337—Polymers modified by chemical after-treatment with organic compounds containing other elements
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/04—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers only
    • C08G65/06—Cyclic ethers having no atoms other than carbon and hydrogen outside the ring
    • C08G65/08—Saturated oxiranes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • C08G65/33317—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)

Abstract

Данное изобретение относится к низкомолекулярным лекарственным веществам, химически модифицированным путем ковалентного связывания с водорастворимым олигомером, полученным из монодисперсной или бимодальной композиции водорастворимых олигомеров. Конъюгат согласно настоящему изобретению при введении любым из ряда способов демонстрирует пониженную скорость проникновения через биологические мембраны по сравнению со скоростью проникновения через биологические мембраны низкомолекулярных лекарственных веществ, не связанных с водорастворимым олигомером.
EA200601167A 2003-12-16 2004-12-16 Композиции, содержащие конъюгаты, способы их получения и применение EA015333B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53012203P 2003-12-16 2003-12-16
PCT/US2004/042661 WO2005058367A2 (en) 2003-12-16 2004-12-16 Pegylated small molecules

Publications (2)

Publication Number Publication Date
EA200601167A1 true EA200601167A1 (ru) 2006-12-29
EA015333B1 EA015333B1 (ru) 2011-06-30

Family

ID=34700098

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201000994A EA018427B1 (ru) 2003-12-16 2004-12-16 Химически модифицированный налоксон
EA200601167A EA015333B1 (ru) 2003-12-16 2004-12-16 Композиции, содержащие конъюгаты, способы их получения и применение

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201000994A EA018427B1 (ru) 2003-12-16 2004-12-16 Химически модифицированный налоксон

Country Status (26)

Country Link
US (2) US7786133B2 (ru)
EP (3) EP2604282B1 (ru)
JP (1) JP4991312B2 (ru)
KR (1) KR101168620B1 (ru)
CN (3) CN102895666B (ru)
AU (2) AU2004299138B2 (ru)
CA (2) CA2758460C (ru)
CY (2) CY1114992T1 (ru)
DK (1) DK1694363T3 (ru)
EA (2) EA018427B1 (ru)
ES (3) ES2445585T3 (ru)
FR (1) FR15C0037I2 (ru)
HK (2) HK1146645A1 (ru)
HR (1) HRP20140361T1 (ru)
HU (1) HUS1500026I1 (ru)
IL (2) IL176317A (ru)
LT (1) LTC1694363I2 (ru)
LU (1) LU92702I2 (ru)
NL (1) NL300737I2 (ru)
NZ (3) NZ583573A (ru)
PL (1) PL1694363T3 (ru)
PT (1) PT1694363E (ru)
RS (1) RS53279B (ru)
SI (1) SI1694363T1 (ru)
WO (1) WO2005058367A2 (ru)
ZA (1) ZA200605763B (ru)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143328A1 (en) * 2001-08-13 2009-06-04 Mcdonald George Method of Treating Cancer by Administration of Topical Active Corticosteroids
CA2463938C (en) 2001-10-18 2011-08-09 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
CN102895666B (zh) 2003-12-16 2015-08-19 尼克塔治疗公司 化学改性的小分子
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
RU2008132149A (ru) 2006-01-05 2010-02-10 Юниверсити Оф Юта Рисерч Фаундейшн (Us) Способы и композиции, имеющие отношение к улучшенным свойствам фармакологических средств, целенаправленно действующих на нервную систему
WO2007100902A2 (en) 2006-02-28 2007-09-07 Oligasis Corporation Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
CN101466381B (zh) 2006-04-21 2012-11-14 尼克塔治疗公司 吗啡酮的立体选择性还原
WO2008057579A2 (en) * 2006-11-07 2008-05-15 Nektar Therapeutics Al, Corporation Dosage forms and co-administration of an opioid agonist and an opioid antagonist
KR100829890B1 (ko) 2007-02-08 2008-05-16 주식회사 바이오폴리메드 신규한 레티놀 유도체, 이의 제조방법 및 이를 포함하는주름 개선용 화장료 조성물
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US20100184989A1 (en) * 2007-03-12 2010-07-22 Nektar Therapeutics De Novo Synthesis of Conjugates
WO2008112287A1 (en) 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-beta blocker conjugates
WO2008112257A1 (en) * 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-antihistamine conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
KR101568428B1 (ko) * 2007-03-12 2015-11-11 넥타르 테라퓨틱스 올리고머―오피오이드 효능제 컨주게이트
WO2011011543A1 (en) 2009-07-21 2011-01-27 Nektar Therapeutics Oligomer-opioid agonist conjugates
AU2014200906B2 (en) * 2007-03-12 2016-07-07 Nektar Therapeutics Oligomer-protease inhibitor conjugates
CN102816111B (zh) 2007-03-12 2014-08-06 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
US8389759B2 (en) * 2007-03-12 2013-03-05 Nektar Therapeutics Oligomer-anticholinergic agent conjugates
WO2009032286A2 (en) * 2007-09-06 2009-03-12 Nektar Therapeutics Al, Corporation Oligomer-calcium channel blocker conjugates
US8741858B2 (en) 2007-09-21 2014-06-03 Zhongxu Ren Oligomer-nucleoside phosphate conjugates
WO2009045539A2 (en) * 2007-10-05 2009-04-09 Nektar Therapeutics Al, Corporation Oligomer-corticosteroid conjugates
US20100303753A1 (en) * 2007-10-19 2010-12-02 Nektar Therapeutics Oligomer Conjugates of Lidocaine and Its Derivatives
WO2009058387A2 (en) 2007-11-02 2009-05-07 Nektar Therapeutics Al, Corporation Oligomer-nitroimidazole anti-infective conjugates
US8536213B2 (en) 2007-11-16 2013-09-17 Nektar Therapeutics Oligomer-dantrolene conjugates and related compounds
CN101878042B (zh) * 2007-11-28 2013-06-19 尼克塔治疗公司 低聚物-三环共轭物
WO2009089053A1 (en) * 2008-01-11 2009-07-16 Nektar Therapeutics Al, Corporation Oligomer-guanidine class conjugates
EP2249872B1 (en) 2008-01-25 2017-03-22 Nektar Therapeutics Oligomer-diarylpiperazine conjugates
WO2009099670A2 (en) * 2008-02-08 2009-08-13 Nektar Therapeutics Al, Corporation Oligomer-cannabinoid conjugates
WO2009105258A1 (en) 2008-02-22 2009-08-27 Nektar Therapeutics Al, Corporation Oligomer conjugates of heteropentacyclic nucleosides
WO2009114153A1 (en) 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-foscarnet conjugates
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
WO2009120358A1 (en) * 2008-03-27 2009-10-01 Nektar Therapeutics Oligomer-nitrogenous base conjugates
EP2265290B1 (en) * 2008-04-11 2014-06-04 Nektar Therapeutics Poly(alkylene oxide)-aryloxy-substituted propanamine conjugates
US9095621B2 (en) 2008-04-25 2015-08-04 Nektar Therapeutics Oligome-bis-chromonyl compound conjugates
ES2648122T3 (es) 2008-04-30 2017-12-28 Immunogen, Inc. Reticulantes y sus usos
MX2010011727A (es) * 2008-05-07 2010-11-30 Nektar Therapeutics Administracion oral de antagonistas opioides que actuan perifericamente.
WO2009151590A2 (en) * 2008-06-09 2009-12-17 Nektar Therapeutics Methods of treating cyp2d6 alternative metabolizers
EP2340044A1 (en) * 2008-09-16 2011-07-06 Nektar Therapeutics Pegylated opioids with low potential for abuse
EP2344201A1 (en) * 2008-09-17 2011-07-20 Nektar Therapeutics Oligomer-protease inhibitor conjugates
US20110195940A1 (en) 2008-09-17 2011-08-11 Nektar Therapeutics Protease Inhibitors Having Enhanced Features
AU2010208274B2 (en) 2009-01-28 2015-11-05 Nektar Therapeutics Oligomer-phenothiazine conjugates
WO2010099200A1 (en) 2009-02-24 2010-09-02 Nektar Therapeutics Oligomer-amino acid conjugates
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2010120388A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2010132693A2 (en) 2009-05-13 2010-11-18 Nektar Therapeutics Oligomer-containing pyrrolidine compounds
MX2011012044A (es) * 2009-05-13 2011-12-14 Nektar Therapeutics Compuestos de triazina aromatica sustituida que contienen oligomeros.
EP2437790B1 (en) 2009-06-03 2019-02-20 Immunogen, Inc. Conjugation methods
WO2010144869A2 (en) 2009-06-12 2010-12-16 Nektar Therapeutics Protease inhibitors
CN105503889B (zh) * 2009-07-21 2019-12-24 尼克塔治疗公司 低聚物-阿片样激动剂轭合物
US8722732B2 (en) 2009-09-29 2014-05-13 Nektar Therapeutics Oligomer-calcimimetic conjugates and related compounds
KR101828613B1 (ko) * 2009-09-29 2018-02-12 넥타르 테라퓨틱스 올리고머-칼슘 모방체 컨쥬게이트 및 관련 화합물
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
WO2011088140A1 (en) 2010-01-12 2011-07-21 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
WO2011091050A1 (en) 2010-01-19 2011-07-28 Nektar Therapeutics Oligomer-tricyclic conjugates
WO2011103559A1 (en) 2010-02-22 2011-08-25 Nektar Therapeutics Oligomer modified diaromatic substituted compounds
US20160015656A2 (en) * 2010-08-05 2016-01-21 Nitto Denko Corporation Composition for regenerating normal tissue from fibrotic tissue
PL2621496T5 (pl) * 2010-09-30 2019-05-31 Astrazeneca Ab Krystaliczny koniugat naloksol-peg
EP2627639B1 (en) 2010-10-15 2021-12-22 Nektar Therapeutics N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides
WO2012079017A1 (en) 2010-12-10 2012-06-14 Nektar Therapeutics Hydroxylated tricyclic compounds
WO2012082995A1 (en) 2010-12-15 2012-06-21 Nektar Therapeutics Oligomer-containing hydantoin compounds
WO2012082942A2 (en) 2010-12-15 2012-06-21 Neuroadjuvants, Inc. Neuropeptide analogs, compositions, and methods for treating pain
WO2012083153A1 (en) 2010-12-16 2012-06-21 Nektar Therapeutics Oligomer-containing apremilast moiety compounds
WO2012088506A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-semaxanib moiety conjugates
MX348933B (es) 2011-11-07 2017-07-03 Nektar Therapeutics Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico.
US10525054B2 (en) 2011-11-07 2020-01-07 Inheris Biopharma, Inc. Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound
CN103289075B (zh) * 2012-02-22 2016-01-20 天津键凯科技有限公司 聚乙二醇与纳洛酮的结合物及其药物组合物和应用
US9375486B2 (en) 2012-09-17 2016-06-28 Nektar Therapeutics Oligomer-containing benzamide-based compounds
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
CN104208715B (zh) * 2013-05-31 2016-12-28 天津键凯科技有限公司 具有提高的药物生物活性的低分子量聚乙二醇药物结合物
US9789198B2 (en) * 2013-05-31 2017-10-17 Jenkem Technology Co., Ltd. (Tianjin) Low molecular weight polyethylene glycol drug conjugates having improved drug biological activity
JP6577943B2 (ja) 2013-06-28 2019-09-18 ネクター セラピューティクス κオピオイド作動薬及びその使用
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
WO2015079459A1 (en) 2013-11-27 2015-06-04 Nektar Therapeutics (India) Pvt.Ltd. Opioid agonists and uses thereof
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10272158B2 (en) * 2014-07-03 2019-04-30 Board Of Regents, The University Of Texas System Compounds for treating biofilm infection
KR102210104B1 (ko) 2014-10-17 2021-02-01 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
WO2016064914A1 (en) 2014-10-20 2016-04-28 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
CN104473927A (zh) * 2014-12-05 2015-04-01 北京键凯科技有限公司 一种聚乙二醇与药物分子结合物及其制备方法
WO2016106133A1 (en) 2014-12-23 2016-06-30 Nektar Therapeutics N-methyl-n-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor
MX2017012982A (es) 2015-04-10 2018-07-06 Univ Jefferson Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
EP3294714B1 (en) 2015-05-08 2023-03-15 Nektar Therapeutics Morphinan derivatives for the treatment of neuropathic pain
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
CN107033154B (zh) 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN107033155B (zh) * 2016-02-04 2019-04-26 国药集团国瑞药业有限公司 一种吗啡酮类化合物的立体选择性还原方法
EP3228307A1 (en) 2016-04-05 2017-10-11 Sandoz Ag Solid dispersion comprising opioid antagonists
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
WO2018096464A1 (en) 2016-11-23 2018-05-31 Aurobindo Pharma Limited Naloxegol oxalate and solid dispersion thereof
US11319408B2 (en) 2017-03-30 2022-05-03 Nof Corporation Hydrophilic polymer derivative having self-immolative acetal linker and conjugate using same
JP6990355B2 (ja) 2017-03-30 2022-01-12 日油株式会社 ヘテロ二官能性単分散ポリエチレングリコール及びそれを用いた複合体
CN109134479A (zh) * 2017-06-27 2019-01-04 石家庄蒎格医药科技有限公司 结晶聚乙二醇纳洛酮草酸盐及制备方法
WO2019058387A1 (en) * 2017-09-19 2019-03-28 Msn Laboratories Private Limited, R&D Center IMPROVED PROCESS FOR THE PREPARATION OF (5Α, 6Α) -17-ALLYL-6- (2,5,8,11,14,17,20-HEPTAOXADOCOSAN-22-YLOXY) -4,5-EPOXYMORPHINANE-3,14-DIOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
EP3766917B1 (en) 2018-03-13 2023-04-19 NOF Corporation Heterobifunctional compound having monodispersed polyethylene glycol in main chain or side chain
JPWO2021060439A1 (ru) 2019-09-26 2021-04-01
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN113827576B (zh) * 2021-11-17 2023-08-01 北京尚修堂医药科技有限公司 一种活性成分为草酸纳洛解的药物组合物及制备方法
IT202200026703A1 (it) 2022-12-23 2024-06-23 Sintalica S R L Composti triptamminici non allucinogeni, preparazione, composizioni farmaceutiche e relativi usi
WO2024172892A1 (en) 2023-02-13 2024-08-22 Zymeron Corporation Plasmonic nanoparticle platform for analyte detection

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223163A (en) * 1976-12-10 1980-09-16 The Procter & Gamble Company Process for making ethoxylated fatty alcohols with narrow polyethoxy chain distribution
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
FR2514644A1 (fr) * 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
US4587046A (en) * 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US4730048A (en) * 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4719215A (en) * 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) * 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
JPH01207320A (ja) 1988-02-15 1989-08-21 Daicel Chem Ind Ltd 芳香族ポリエーテルの製造方法
IT1216687B (it) * 1988-04-01 1990-03-08 Boehringer Biochemia Srl Complessi di platino (ii), loro preparazione e impiego come antitumorali.
US5102887A (en) * 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
DE69030829T2 (de) * 1989-03-10 1998-01-15 Hoffmann La Roche Reagenzien zum Nachweis von Drogen
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
JPH0383914A (ja) * 1989-08-18 1991-04-09 W R Grace & Co ドラッグキャリアー
DE3937797A1 (de) * 1989-11-14 1991-05-16 Basf Ag Verfahren zur herstellung von polyetherglykolen
US5130126A (en) * 1990-07-09 1992-07-14 Nippon Oil & Fats Co., Ltd. Polymer-drug conjugate and a method of producing it
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0599303A3 (en) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
KR100321649B1 (ko) * 1993-03-17 2002-07-22 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 에스테르,아미드또는머캅토에스테르로부터유도된분산보조제를함유하는에어로졸제제
WO1995000162A1 (en) * 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5434171A (en) 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5670477A (en) * 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
JP4050314B2 (ja) 1995-06-07 2008-02-20 オーソ ファーマシューティカル コーポレイション エリトロポエチン受容体に結合する化合物およびペプチド
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
AU730969B2 (en) 1995-10-19 2001-03-22 University Of Washington Discrete-length polyethylene glycols
US5639705A (en) * 1996-01-19 1997-06-17 Arco Chemical Technology, L.P. Double metal cyanide catalysts and methods for making them
DE69709646T2 (de) * 1996-03-12 2002-08-14 Alza Corp., Palo Alto Zusammensetzung und dosisform mit einem opioid-antagonisten
US5856369A (en) 1996-07-30 1999-01-05 Osi Specialties, Inc. Polyethers and polysiloxane copolymers manufactured with double metal cyanide catalysts
DE19632440A1 (de) 1996-08-12 1998-02-19 Basf Ag Verfahren zur Herstellung von aus Polykationen aufgebauten, geformten Mischhydroxiden
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6011008A (en) * 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US5972954A (en) * 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
AU1825299A (en) * 1997-12-17 1999-07-05 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
DE69939033D1 (de) * 1998-03-12 2008-08-14 Nektar Therapeutics Al Corp Verfahren zur Herstellung von Polymerkonjugaten
US6316644B1 (en) * 1998-03-30 2001-11-13 Lg Chemical Ltd. Pilyethoxylated retinamide derivatives and process for preparing the same
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
EP0995757A3 (en) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
KR100345214B1 (ko) 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6380405B1 (en) * 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
DE60044070D1 (de) * 1999-10-29 2010-05-06 Novartis Ag Trockenpulverzusammensetzungen mit verbesserter Dispersität
WO2001046291A1 (en) * 1999-12-22 2001-06-28 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
WO2001062299A2 (en) * 2000-02-28 2001-08-30 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
WO2001068080A2 (en) * 2000-03-15 2001-09-20 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU2001285311B2 (en) * 2000-08-29 2005-09-15 Biocon, Ltd Immunoregulatory compounds, derivatives thereof and their use
US7829074B2 (en) * 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
JP2004514701A (ja) 2000-11-30 2004-05-20 ネクター　セラピューティクス　エーエル，コーポレイション トリアジン誘導体の水溶性ポリマー複合体
PT1349855E (pt) * 2000-12-22 2006-12-29 Smithkline Beecham Plc Sal misilato de 5-{4-[2-(n-metil-n-(2-piridil)amino)etoxi]benzil}tiazolidino-2, 4-diona
EP1362053B1 (en) * 2001-02-20 2007-11-14 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US20020169125A1 (en) * 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6756354B2 (en) * 2001-09-05 2004-06-29 Deanna Jean Nelson Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates
CA2463938C (en) * 2001-10-18 2011-08-09 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
MXPA04004026A (es) * 2001-10-29 2004-07-08 Nektar Therapeutics Al Corp Conjugados polimericos de inhibidores de la proteina quinasa c.
ATE359829T1 (de) * 2001-10-30 2007-05-15 Nektar Therapeutics Al Corp Wasserlösliche polymerkonjugate von retinoesäure
WO2003051113A1 (en) 2001-12-14 2003-06-26 The University Of Wyoming Methods and compositions for controlled release of drugs
US20040152769A1 (en) 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
EP1603597B1 (en) * 2003-03-13 2010-01-06 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
GB0317815D0 (en) * 2003-07-30 2003-09-03 Amersham Health As Imaging agents
AU2004264818B2 (en) 2003-08-01 2011-09-29 Biocon, Ltd Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same
ES2445948T3 (es) * 2003-11-24 2014-03-06 Ratiopharm Gmbh Eritropoyetina glicopegilada
CN102895666B (zh) 2003-12-16 2015-08-19 尼克塔治疗公司 化学改性的小分子
CN101466381B (zh) * 2006-04-21 2012-11-14 尼克塔治疗公司 吗啡酮的立体选择性还原

Also Published As

Publication number Publication date
HRP20140361T1 (hr) 2014-05-23
US20050136031A1 (en) 2005-06-23
EP1694363A2 (en) 2006-08-30
DK1694363T3 (en) 2014-03-24
JP2007514761A (ja) 2007-06-07
HK1210418A1 (en) 2016-04-22
SI1694363T1 (sl) 2014-03-31
PL1694363T3 (pl) 2014-07-31
EP2604282A1 (en) 2013-06-19
NZ548529A (en) 2010-08-27
EA201000994A2 (ru) 2011-08-30
EP2905033A1 (en) 2015-08-12
PT1694363E (pt) 2014-02-20
AU2010202277A1 (en) 2010-06-24
HUS1500026I1 (hu) 2017-10-30
CY2015019I1 (el) 2016-12-14
CN102895666B (zh) 2015-08-19
AU2004299138A1 (en) 2005-06-30
RS53279B (en) 2014-08-29
ZA200605763B (en) 2007-04-25
AU2010202277B2 (en) 2013-03-21
CA2549730C (en) 2012-02-14
HK1146645A1 (en) 2011-06-24
CN102895666A (zh) 2013-01-30
IL229509A (en) 2016-05-31
CA2758460C (en) 2014-09-23
LTC1694363I2 (lt) 2017-05-10
FR15C0037I2 (fr) 2016-09-30
CA2758460A1 (en) 2005-06-30
IL176317A0 (en) 2006-10-05
WO2005058367A3 (en) 2006-03-30
ES2445585T3 (es) 2014-03-04
LU92702I2 (fr) 2016-07-29
EP2905033B1 (en) 2020-09-02
IL229509A0 (en) 2013-12-31
CY1114992T1 (el) 2016-12-14
CA2549730A1 (en) 2005-06-30
EP1694363B1 (en) 2014-01-22
ES2733764T3 (es) 2019-12-02
NL300737I2 (ru) 2017-01-31
FR15C0037I1 (ru) 2015-06-26
CN101805343B (zh) 2014-04-16
ES2817799T3 (es) 2021-04-08
AU2004299138B2 (en) 2010-03-25
CN101805343A (zh) 2010-08-18
CN1925875A (zh) 2007-03-07
JP4991312B2 (ja) 2012-08-01
EA018427B1 (ru) 2013-07-30
KR101168620B1 (ko) 2012-08-03
EP2604282B1 (en) 2019-06-19
US7786133B2 (en) 2010-08-31
US20100305147A1 (en) 2010-12-02
NZ583573A (en) 2011-12-22
EA015333B1 (ru) 2011-06-30
IL176317A (en) 2014-01-30
WO2005058367A2 (en) 2005-06-30
EA201000994A3 (ru) 2011-10-31
US8034825B2 (en) 2011-10-11
KR20060126714A (ko) 2006-12-08
NZ594834A (en) 2013-03-28
CY2015019I2 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
EA200601167A1 (ru) Химически модифицированные малые молекулы
Zhang et al. Dendritic cell lectin-targeting sentinel-like unimolecular glycoconjugates to release an anti-HIV drug
ATE533513T1 (de) Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel
WO2008076333A8 (en) Polymer-drug conjugates with tether groups for controlled drug delivery
WO2007014784A3 (en) Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation
DE502006007655D1 (de) Präparate umfassend hyperverzweigte polymere
GEP20063917B (en) Pulmonary administration of chemically modified insulin
WO2007100905A3 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
JO2932B1 (en) Lyspro insulin compounds linked to PEG
WO2007004236A3 (en) Improved drug or pharmaceutical compounds and a preparation thereof
EP2374480A3 (en) Mutli-drug ligand conjugates
GB2430367B (en) Ion binding polymers and uses thereof
AU2003267581A1 (en) Drug delivery
EP2471527A3 (en) Facially amphiphillc polymers and oligomers and uses thereof
WO2009042064A3 (en) Oligomer-nucleoside phosphate conjugates
BR112012015606A2 (pt) "combinações anticâncer de farmacos baseados em artemisinina e outros agentes quimioterápicos"
Yilmaz et al. Glycopolymer Code: Programming Synthetic Macromolecules for Biological Targeting
Diaz-Dussan et al. Oncogenic epidermal growth factor receptor silencing in cervical carcinoma mediated by dynamic sugar-benzoxaborole polyplexes
WO2007067333A3 (en) Trioxane dimers having high anticancer and long-lasting antimalarial activities
WO2008008387A9 (en) Drug delivery polyanhydride composition and method
WO2009045539A3 (en) Peg-corticosteroid conjugates
WO2010033204A3 (en) Polymer conjugates of c-peptides
WO2004091542A3 (en) Nitrogen containing integrin targeting compounds
WO2009032286A3 (en) Oligomer-calcium channel blocker conjugates
WO2005077385A3 (en) Methods for treating resistant or refractory tumors